EARS News and Press, Auris Medical Holding AG From 04/05/19

Auris Medical Holding (NASDAQ: EARS ) is 3.2% lower after hours as a holder files to offer up to 10M shares . More news on: Auris Medical Holding Ltd., Healthcare stocks news, Stocks on the move, Read more ...

Hamilton, Bermuda, March 29, 2019 - Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the first cohort of subjects have...

Zug, Switzerland, March 15, 2019 (GLOBE NEWSWIRE) -- March 14, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, announced today that i...

CORAL GABLES, FL / ACCESSWIRE / March 14, 2019 / Over the last few months, the healthcare stock market has captivated media attention as companies in the healthcare sector have focused their efforts on developing innovative treatment options and care solutions for patients suffering from a...

Auris Medical Holding AG (EARS) Q4 2018 Earnings Conference Call March 14, 2019 08:00 AM ET Company Participants Thomas Meyer - CEO Hernan Levett - CFO Conference Call Participants Jim Molloy - AGP Briana Warschun - Edison Group Presentation Operator Good morning,...

The following slide deck was published by Auris Medical Holding AG in conjunction with their 2018 Q4 earnings Read more ...

Auris Medical ( EARS ) Q4 results (CHF): Revenues: 0; R&D Expense: 0.03M (-99.3%); SG&A: 0.6M (-50.0%); Net Loss: (3.7M) (+19.6%); Loss Per Share: (0.12) (+88.6%); Quick Assets: 5.4M (-64.0%). More news on: Auris Medical Holding AG, Healthcare stocks news, Earnings news and comme...

Auris Medical (NASDAQ: EARS ): Q4 GAAP EPS of -CHF0.12. More news on: Auris Medical Holding AG, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

Phase 1 trial confirmed superior bioavailability of intranasal betahistine as well as good safety and tolerability Intranasal betahistine program progressing towards proof-of-concept studies in acute vertigo (AM-125) and antipsychotic-induced weight gain (AM-201) Detailed results fr...

Zug, Switzerland, March 11, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the publication of an article that presen...